News

Filter

Current filters:

Rare diseases

1 to 9 of 565 results

Blueprint Medicines in up to $265 million deal with Alexion

03-03-2015

Privately-held Blueprint Medicines has entered a strategic collaboration with USA-based Alexion Pharmaceuticals…

Alexion PharmaceuticalsBlueprint MedicinesLicensingPharmaceuticalRare diseases

Oncolytics Biotech gains third orphan status for Reolysin

Oncolytics Biotech gains third orphan status for Reolysin

03-03-2015

Canada’s Oncolytics Biotech revealed today that the US Food and Drug Administration has granted Orphan…

BiotechnologyOncologyOncolytics BiotechRare diseasesRegulationReolysinUSA

PHARMAC in negotiations over rare disorders medicines

PHARMAC in negotiations over rare disorders medicines

27-02-2015

New Zealand’s Pharmaceutical Management Agency, PHARMAC, is in active negotiations with several suppliers…

FinancialHealthcareNew ZealandPharmaceuticalPricingRare diseases

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

Shire acquires Meritage Pharma, strengthening rare diseases pipeline

24-02-2015

In a second acquisition this year, Ireland-headquartered Shire revealed today that it has taken control…

BiotechnologyGastro-intestinalsMergers & AcquisitionsMeritage PharmaRare diseasesShire

Marathon Pharma sells non-strategic products to Valeant

24-02-2015

Marathon Pharmaceuticals, a privately held US biopharmaceuticals company focused on drugs for people…

Marathon PharmaceuticalsMergers & AcquisitionsPharmaceuticalRare diseasesValeant Pharmaceuticals International

Sosei acquires Heptares Therapeutics for up to $400 million

Sosei acquires Heptares Therapeutics for up to $400 million

23-02-2015

Japanese drugmaker Sosei Group says it has acquired Heptares Therapeutics, a clinical-stage private UK-based…

BiotechnologyHeptares TherapeuticsMergers & AcquisitionsNeurologicalRare diseasesSosei

EMA Orphan Drug status for aTyr’s Resolaris in FSHD

18-02-2015

Privately-held US biotech firm aTyr Pharma says that the European Commission has granted Orphan Drug…

ATyr PharmaBiotechnologyEuropeRare diseasesRegulationResolaris

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

Australia to subsidize Genzyme’s Pompe disease drug Myozyme for young patients

17-02-2015

Australia’s Minister for Health Sussan Ley said today that she has approved a life-saving drug that…

AustraliaBiotechnologyFinancialGenzymeHealthcareMyozymeRare diseasesSanofi

1 to 9 of 565 results

COMPANY SPOTLIGHT

Menarini

Back to top